DocGo Financials
DCGO Stock | USD 4.89 0.04 0.82% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Debt Equity Ratio | 0.18 | 0.1546 |
|
| |||||
Current Ratio | 3.89 | 2.29 |
|
|
Investors should never underestimate DocGo's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor DocGo's cash flow, debt, and profitability to make informed and accurate decisions about investing in DocGo Inc.
Net Income |
|
DocGo | Select Account or Indicator |
Understanding current and past DocGo Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of DocGo's financial statements are interrelated, with each one affecting the others. For example, an increase in DocGo's assets may result in an increase in income on the income statement.
DocGo Stock Summary
DocGo competes with Enhabit, Ensign, Pennant, InnovAge Holding, and National HealthCare. DocGo, Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. DocGo, Inc. was incorporated in 2015 and is headquartered in New York, New York. Docgo operates under Medical Care Facilities classification in the United States and is traded on NASDAQ Exchange. It employs 1706 people.Specialization | Health Care, Health Care Equipment & Services |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US2560861096 |
CUSIP | 256086109 61980M107 |
Location | New York; U.S.A |
Business Address | 35 West 35th |
Sector | Health Care Equipment & Supplies |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.docgo.com |
Phone | 844 443 6246 |
Currency | USD - US Dollar |
DocGo Key Financial Ratios
Return On Equity | 0.0941 | ||||
Profit Margin | 0.04 % | ||||
Operating Margin | 0.07 % | ||||
Price To Sales | 0.71 X | ||||
Revenue | 624.29 M |
DocGo Key Balance Sheet Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Total Assets | 100.2M | 309.6M | 393.3M | 490.5M | 564.0M | 306.8M | |
Other Current Liab | 15.4M | 736.0K | 72.9M | 119.0M | 136.8M | 143.6M | |
Net Debt | (18.5M) | (159.0M) | (137.4M) | (12.8M) | (11.5M) | (12.1M) | |
Retained Earnings | (87.3M) | (63.6M) | (29.0M) | (21.4M) | (24.6M) | (25.8M) | |
Accounts Payable | 4.0M | 15.8M | 21.6M | 19.8M | 22.8M | 13.7M | |
Cash | 32.4M | 175.5M | 157.3M | 59.3M | 68.2M | 103.9M | |
Long Term Debt | 594.5K | 14.8M | 1.2M | 41.6K | 37.4K | 35.6K | |
Net Receivables | 24.9M | 78.4M | 103.0M | 262.1M | 301.4M | 316.5M | |
Good Will | 6.6M | 8.7M | 38.9M | 47.5M | 54.7M | 57.4M | |
Other Current Assets | 1.2M | 2.1T | 10.8M | 17.5M | 20.1M | 19.1M | |
Total Liab | 33.2M | 82.5M | 114.4M | 185.3M | 213.1M | 223.7M | |
Net Invested Capital | 56.3M | 221.5M | 275.1M | 325.9M | 374.7M | 208.7M | |
Short Long Term Debt | 664.4K | 626.3K | 664.9K | 25.0M | 28.8M | 30.2M | |
Total Current Assets | 58.4M | 256.0M | 271.1M | 338.9M | 389.7M | 216.4M | |
Net Working Capital | 34.9M | 198.2M | 170.9M | 168.8M | 194.1M | 136.9M | |
Short Term Debt | 4.2M | 5.4M | 5.7M | 31.3M | 36.0M | 37.8M | |
Intangible Assets | 10.7M | 10.7M | 23.0M | 37.7M | 43.3M | 45.5M |
DocGo Key Income Statement Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Tax Provision | 167.4K | 615.7K | (8.0M) | 6.2M | 7.2M | 7.5M | |
Net Interest Income | (204.6K) | (763.0K) | 762.7K | 1.7M | 1.9M | 2.0M | |
Interest Expense | 204.6K | 763.0K | 762.7K | 1.7T | 1.9T | 2.0T | |
Total Revenue | 94.1M | 318.7M | 440.5M | 624.3M | 717.9M | 753.8M | |
Gross Profit | 31.3M | 109.7M | 154.7M | 195.4M | 224.7M | 235.9M | |
Operating Income | (14.8M) | 10.5M | 21.8M | 15.1M | 17.3M | 18.2M | |
Ebit | (14.8M) | 20.6M | 21.8M | 15.3M | 17.6M | 18.5M | |
Research Development | 1.2M | 3.3M | 5.4M | 10.9M | 12.5M | 13.1M | |
Ebitda | (9.3M) | 28.1M | 32.4M | 31.8M | 36.5M | 38.3M | |
Cost Of Revenue | 62.7M | 209.0M | 285.8M | 428.9M | 493.2M | 517.9M | |
Income Before Tax | (14.6M) | 19.8M | 22.8M | 16.3M | 18.7M | 19.7M | |
Net Income | (14.8M) | 23.7M | 34.6M | 6.9M | 7.9M | 6.4M | |
Income Tax Expense | 167.4K | 615.7K | (8.0M) | 6.2M | 7.2M | 7.5M | |
Minority Interest | 439.3K | (4.6M) | (3.8M) | (3.2M) | (2.9M) | (3.0M) |
DocGo Key Cash Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Investments | (6.0M) | (655.9K) | (38.4M) | (29.9M) | (26.9M) | (25.5M) | |
Change In Cash | (17.3M) | 144.6M | (15.0M) | (91.9M) | (82.7M) | (78.6M) | |
Free Cash Flow | (17.0M) | (8.6M) | 23.4M | (74.3M) | (66.9M) | (63.6M) | |
Depreciation | 5.5M | 7.1M | 10.6M | 16.4M | 18.9M | 9.6M | |
Other Non Cash Items | (300K) | (142.7K) | 2.6M | 6.6M | 7.6M | 8.0M | |
Capital Expenditures | 6.3M | 6.7M | 5.5M | 10.1M | 11.6M | 7.1M | |
Net Income | (14.8M) | 19.2M | 30.7M | 6.9M | 7.9M | 4.6M | |
End Period Cash Flow | 34.5M | 179.1M | 164.1M | 72.2M | 83.1M | 110.4M |
DocGo Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining DocGo's current stock value. Our valuation model uses many indicators to compare DocGo value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across DocGo competition to find correlations between indicators driving DocGo's intrinsic value. More Info.DocGo Inc is rated below average in return on equity category among its peers. It is rated # 3 in return on asset category among its peers reporting about 0.70 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for DocGo Inc is roughly 1.43 . At this time, DocGo's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the DocGo's earnings, one of the primary drivers of an investment's value.DocGo Inc Systematic Risk
DocGo's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. DocGo volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on DocGo Inc correlated with the market. If Beta is less than 0 DocGo generally moves in the opposite direction as compared to the market. If DocGo Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one DocGo Inc is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of DocGo is generally in the same direction as the market. If Beta > 1 DocGo moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in DocGo Stock are looking for potential investment opportunities by analyzing not only static indicators but also various DocGo's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of DocGo growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
DocGo February 2, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of DocGo help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of DocGo Inc. We use our internally-developed statistical techniques to arrive at the intrinsic value of DocGo Inc based on widely used predictive technical indicators. In general, we focus on analyzing DocGo Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build DocGo's daily price indicators and compare them against related drivers.
Downside Deviation | 2.67 | |||
Information Ratio | 0.1709 | |||
Maximum Drawdown | 15.68 | |||
Value At Risk | (4.00) | |||
Potential Upside | 4.66 |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DocGo Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DocGo. If investors know DocGo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DocGo listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.09 | Earnings Share 0.29 | Revenue Per Share | Quarterly Revenue Growth (0.26) | Return On Assets |
The market value of DocGo Inc is measured differently than its book value, which is the value of DocGo that is recorded on the company's balance sheet. Investors also form their own opinion of DocGo's value that differs from its market value or its book value, called intrinsic value, which is DocGo's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DocGo's market value can be influenced by many factors that don't directly affect DocGo's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DocGo's value and its price as these two are different measures arrived at by different means. Investors typically determine if DocGo is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DocGo's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.